Schonfeld Strategic Advisors’s Bicara Therapeutics BCAX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCAX
SL
Schonfeld Strategic Advisors's BCAX Position: Q3 2026 in Review
Schonfeld Strategic Advisors opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 23,752 shares worth $442K. The stake represents ﹤0.01% of the portfolio and ranks #2026 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in BCAX as recently as Q3 2025.
Schonfeld Strategic Advisors first reported a position in BCAX in Q1 2025 and has held it in 4 quarters since. The position peaked at $7.96M in Q3 2025. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.
- Schonfeld Strategic Advisors held 23,752 shares of Bicara Therapeutics worth $442K as of Q3 2026.
- Bicara Therapeutics was a new Schonfeld Strategic Advisors position in Q3 2026.
- Bicara Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q3 2026, its #2026 holding.
- Schonfeld Strategic Advisors first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 4 quarters since.
- Schonfeld Strategic Advisors's Bicara Therapeutics position peaked at $7.96M in Q3 2025.
- 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.